The Danish Company Behind Ozempic

Novo Nordisk, the Danish company behind weight loss drugs Wegovy and Ozempic, reached a market value of $500 billion. The company's non-profit foundation ownership and corporate structure are discussed, along with its impact on research advances. The podcast also explores Novo Nordisk's role in the Danish economy, collaborations with artists to address obesity, power dynamics in the pharmaceutical industry, and the economic implications of anti-obesity drugs.